Skip to main content

Table 2 Impact of covariates on time to discontinuation: multivariate Cox regression analysis adjusting for baseline characteristics in all eligible patients (N = 1798)a

From: A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain

 

Target OAB drug received

Treatment status

Age, years

Mirabegron

(N = 1169)b

Antimuscarinics

(N = 629)

Naïve

(N = 1289)

Experienced

(N = 509)b

45–64

(N = 649)

65–74

(N = 595)

≥75

(N = 554)b

TTD

 Median, days

90

56

60

99

60

90

91

 (95% CI)

90–92

30–56

60–61

92–121

56–60

68–91

90–99

 HR (95% CI)

1.52 (1.37–1.70)c

1.35 (1.20–1.53)c

1.53 (1.35–1.74)c

1.15 (1.011.31)d

  1. ATC Anatomical Therapeutic Chemical, CI confidence intervals, GP general practitioner, HR hazard ratio, OAB overactive bladder, TTD time to discontinuation
  2. aAt index date; HR, 95% CI and p-values generated using a stepwise Cox regression model including target OAB drug received, treatment status and age
  3. bReference comparator
  4. cp < 0.001
  5. dp = 0.039 (all other comparisons non-significant)